ANCA-Negative, Nerve-Positive: When a Biologic's Own Approval Population Doesn't Cover the Nerve
A single patient with new mononeuritis multiplex from eosinophilic granulomatosis with polyangiitis. The disagreement is over whether his ANCA-negative status should point toward a gentler biologic, or whether his actively damaged nerve overrides that reading entirely.
Gerald N., 51, has taught high school shop class for two decades, work that means he's on his feet all day among table saws and drill presses, which is exactly why the new numbness and dragging in his left foot alarmed him enough to come in before it got worse. His asthma has been part of his life since his thirties, along with chronic sinus polyps that have needed surgery twice — a history that, combined with the new palpable purpura now spreading across both lower legs and an eosinophil count of 4,200, points squarely toward eosinophilic granulomatosis with polyangiitis. Nerve conduction studies confirmed what the exam already suggested: mononeuritis multiplex, an asymmetric pattern of nerve damage in his left peroneal and tibial distribution — active, ongoing axonal injury, not a diffuse or symmetric neuropathy. His ANCA came back negative for both major subtypes, which places him among the majority of EGPA patients whose disease is more eosinophil-driven than classically ANCA-mediated — a real biological distinction, though one that sits uneasily next to a nerve that is, right now, actively being damaged regardless of which antibody is or isn't present.
Mepolizumab's approval in EGPA rests on MIRRA, which showed real, meaningful benefit — more accrued time in remission, meaningfully less steroid exposure. A post-hoc analysis of that trial found benefit irrespective of ANCA status, which is often shorthanded into an argument for starting mepolizumab in ANCA-negative patients specifically; the numbers don't actually say that. Remission at weeks 36 and 48 was reached by 54% of patients with a history of ANCA positivity and 27% of those without. 'Irrespective' means it works in both groups, not that his negative serology recommends it. And MIRRA's population was, by design, relapsing or refractory disease already stabilized on at least four weeks of oral glucocorticoids, with organ-threatening or life-threatening EGPA in the prior three months an explicit exclusion — not new, actively evolving organ-threatening vasculitis — and mononeuritis multiplex is specifically the kind of finding severity frameworks treat as organ-threatening, because nerve damage from active vasculitic injury doesn't reliably reverse once it's occurred. Gerald's own presentation sits at the exact seam those two facts create: a serology that fits the eosinophil-driven, potentially gentler-course phenotype mepolizumab was validated in, alongside a clinical finding that the same evidence base was never built to treat as a first-line, sole therapy. Reading his ANCA status and his EMG as pointing toward the same treatment decision turns out to require choosing which one to let govern.
Serology or organ damage
His ANCA-negative status is a real, meaningful marker of a more eosinophil-driven disease process, and MIRRA's post-hoc analysis showed benefit irrespective of ANCA status — I'll concede up front that 'irrespective' isn't the same as 'better in ANCA-negative patients,' and the remission numbers actually ran higher in the ANCA-positive group. Cyclophosphamide's toxicity — infertility risk, malignancy risk over a lifetime — is substantial for an otherwise active fifty-one-year-old, and I'd rather start with the gentler, mechanistically well-matched option.
I'd weight the mononeuritis multiplex more heavily than the ANCA result. Active, asymmetric nerve damage is recognized as an organ-threatening manifestation regardless of serology, precisely because axonal injury from active vasculitis doesn't reliably reverse once it's happened — this isn't a symptom that can safely wait to see if a slower-acting agent gets there in time. That calls for induction, not maintenance-tier therapy, as the first move.
MIRRA showed real benefit irrespective of ANCA status, but organ-threatening disease in the preceding three months was an explicit exclusion criterion — the trial deliberately did not enroll the patient in front of us. Its population was stable patients already on four or more weeks of glucocorticoids, not new, actively evolving neurologic vasculitis. That's a different clinical situation than the one Gerald is actually in.
I'd resolve this by sequence rather than by picking one reading of his serology over the other. Start high-dose glucocorticoids and cyclophosphamide now for the active nerve injury — that's the guideline-consistent response to an organ-threatening manifestation, independent of ANCA status. Once that's controlled, mepolizumab has a genuine, well-supported role as the maintenance agent that lets his steroid exposure come down faster than continued immunosuppression alone would allow. His ANCA-negative status doesn't argue against acute induction — it argues for transitioning to mepolizumab sooner once the acute threat is controlled, rather than never using it at all.
Agreed: start high-dose glucocorticoids and cyclophosphamide induction now for the active mononeuritis multiplex, with mepolizumab planned explicitly as the maintenance transition once the acute manifestation is controlled.
Not fully settled: how many cyclophosphamide cycles to give before transitioning — the allergist/pulmonologist would prefer the shortest course that controls the nerve injury, moving to mepolizumab as early as safely possible, while the rheumatologist wants clearer evidence of neurologic stabilization first, given how much harder unresolved active vasculitis is to treat than a slightly longer induction course.